Autonomix Medical Appoints Sandra Kalter to Board

What Happened

• Autonomix Medical, Inc. filed a Form 8-K (Item 5.02) reporting that on September 14, 2026 the Board increased its size from five to six directors and appointed Sandra Kalter as an independent director, effective immediately.
• Ms. Kalter most recently served in senior regulatory leadership roles at Medtronic plc (May 2011–Jan 2025) and worked as a Strategic Advisor to iTolerance from Nov. 2025 to Apr. 2026. The company also filed a related press release as an exhibit.

Key Details

• Board change effective date: September 14, 2026; Board size increased from five to six members.
• New director: Sandra Kalter — former Chief Regulatory Counsel and Vice‑President at Medtronic (May 2011–Jan 2025).
• Compensation: Ms. Kalter will participate in the company’s standard non‑employee director compensation program.
• Governance/independence: No committee appointment yet; no arrangements, family relationships, or reportable related‑party interests disclosed.

Why It Matters

• This adds experienced regulatory and medical‑device expertise to the Board, which can be relevant for oversight of product development, regulatory strategy and compliance.
• The appointment increases Board capacity without any disclosed conflicts, and the director will be compensated under the standard non‑employee program — facts investors can track in future filings for any committee assignments or potential governance impacts.